Why is CDC concerned about Lyme disease?
Lyme disease is the most common vector-borne disease in the United States. A recently released estimate based on insurance records suggests that approximately 476,000 Americans are diagnosed and treated for Lyme disease each year. In addition to a large burden of illness, areas where Lyme disease is common are expanding.
1 dot placed randomly within county of residence for each confirmed case
Each dot represents one case of Lyme disease and is placed randomly in the patient’s county of residence. The presence of a dot in a state does not necessarily mean that Lyme disease was acquired in that state. People travel between states, and the place of residence is sometimes different from the place where the patient became infected. Many high incidence states have modified surveillance practices. Contact your state health department for more information.
* Changes in state surveillance practices have decreased cases reported by Massachusetts in recent years; Lyme disease remains common in the state.
What is CDC doing about Lyme disease?
Developing better insect repellents
CDC researchers have discovered that a naturally occurring compound called nootkatone, found in grapefruit, Alaska yellow cedar trees, and some herbs, can kill or repel ticks and insects. On August 10, 2020, the Environmental Protection Agency (EPA) registered nootkatone, an active ingredient discovered and developed by DVBD, for use in repellents and insecticides. CDC’s work with licensed partner, Evolva, demonstrates that nootkatone effectively repels and kills mosquitoes and ticks at rates similar to products already on the market. Commercial products using the ingredient could be available as early as 2022.
Evaluating products used by the public
CDC and university partners have evaluated the effectiveness of permethrin-treated clothing as a way to prevent tick bites. Results from a pilot studyexternal icon and a follow-up show that treated fabric is highly irritating to ticks, causing them to drop off and stunting the activity for more than 24 hours afterwards.
Educating the public
CDC has developed and distributed a variety of educational materials–ranging from trail signs to patient information sheets–that are free to download or order. CDC’s Lyme disease website reaches over 7 million people annually and our distribution center has sent out over 30,000 trail signs, 350,000 brochures, and 400,000 prevention bookmarks in the last 5 years.
Promoting collaborative approaches to understanding Lyme and other tickborne diseases
Supporting coordinated research efforts through TickNET
CDC’s TickNET program was established by CDC in 2007 to bring together expertise from state public health partners, CDC, and research scientists. TickNET fosters coordinated surveillance, education, and research on the prevention of tickborne diseases. For more information, see TickNET—A collaborative public health approach to tickborne disease surveillance and research.
Funding state health departments to improve surveillance and prevention
CDC provides funds to state health departments for Lyme and tickborne disease surveillance through the Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) Cooperative Agreement. This money coupled with CDC’s subject matter expertise helps state public health departments strengthen their ability to detect, respond to, control, and prevent Lyme and other tickborne diseases.
Supporting vector-borne disease Centers of Excellence
CDC has awarded nearly $50 million to five universities to establish regional Centers of Excellence to help effectively address emerging vector-borne diseases in the United States. Scientists and public health experts at the Northeastexternal icon and Midwestexternal icon Regional Centers of Excellence will have a strong research component involving the surveillance and control of disease-carrying ticks.
Supporting large-scale prevention research
CDC is contributing both funding and technical expertise to The Tick Projectexternal icon, a 5-year study to determine whether neighborhood-based interventions can reduce cases of Lyme and other tickborne diseases in people. The study will determine whether two tick control methods, used separately or together, can reduce the number of cases of Lyme disease at the neighborhood level. This large-scale research will involve 24 neighborhoods and over 1,000 households.
Discovering new tickborne diseases
CDC is partnering with the Minnesota Department of Health, Mayo Clinic, Tennessee Department of Health, and Vanderbilt University to obtain up to 30,000 clinical specimens from patients with suspected tickborne illness over a 3-year period. CDC will use advanced molecular detection (AMD) methods to identify tickborne bacteria that may be the cause of these patients’ illnesses. Already, investigators have used AMD to sequence the full genome of a newly discovered bacteria, Borrelia mayonii, which is another cause of Lyme disease in upper Midwestern states.
Using advanced molecular detection (AMD) techniques, CDC researchers analyzed over 13,000 leftover samples for the presence of bacteria from patients who were suspected of having tickborne illness. Twelve tickborne species of bacteria that cause illness in people were detected, including two not previously associated with human illness. This large-scale study involving researchers from the Minnesota Department of Health, Mayo Clinic, Tennessee Department of Health, and Vanderbilt University, showed that a single advanced molecular detection test can be used to:
- Detect tickborne bacterial pathogens in clinical samples
- Discover bacteria not previously associated with human infection, that are likely transmitted to humans by tick bite
- Identify tick-transmitted bacterial co-infections
- Understand which bacterial infections can cause symptoms that may be confused with tickborne diseases
Ultimately, AMD techniques may help to simplify diagnostic testing as well as inform tickborne disease surveillance efforts by identifying new tickborne threats.
Understanding attitudes towards vaccination for Lyme disease
CDC is currently conducting research to understand what concerns healthcare providers and the public may have about any potential Lyme disease vaccines.